(Q34539238)

2 August 2017

title

Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting (English)

1 reference

2 August 2017

0 references

1 reference

1 reference

1 reference

Oliver Senn

3

0 references

Thomas Rosemann

series ordinal

2

object named as

Thomas Rosemann

1 reference

2 August 2017

André Seidenberg

1

1 reference

2 August 2017

publication date

8 January 2013

1 reference

2 August 2017

published in

BMC Infectious Diseases

1 reference

2 August 2017

volume

13

1 reference

2 August 2017

page(s)

9

1 reference

Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials.

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

A new standard of care for the treatment of chronic HCV infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

Public health impact of antiviral therapy for hepatitis C in the United States

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

Rate and predictors of treatment prescription for hepatitis C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

Barriers to the treatment of hepatitis C. Patient, provider, and system factors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

Methadone maintenance treatment in the Swiss Canton of Vaud: demographic and clinical data on 1,782 ambulatory patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

Sex, drugs and HIV counseling and testing: a prospective study of behavior-change among methadone-maintenance clients in New England

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3548742

Treatment rates in patients with chronic hepatitis C after liver biopsy

7 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

The impact of injecting drug use status on hepatitis C-related referral and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

Determinants of successful chronic hepatitis C case finding among patients receiving opioid maintenance treatment in a primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

Curing hepatitis C with pills: a step toward global control

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-13-9

Hepatitis C virus and liver transplantation

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23298178

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2334-13-9

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference

2 August 2017

1 reference